Mirmomen, S. Mojdeh
Sirajuddin, Arlene
Nikpanah, Moozhan
Symons, Rolf
Paschall, Anna K.
Papageorgiou, Ioannis
Gahl, William A.
O’Brien, Kevin
Estrada-Veras, Juvianee I.
Malayeri, Ashkan A.
Funding for this research was provided by:
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Cancer Institute
NIH Clinical Center
Article History
Received: 4 October 2017
Revised: 20 February 2018
Accepted: 8 March 2018
First Online: 7 May 2018
Compliance with ethical standards
:
: The scientific guarantor of this publication is Ashkan A. Malayeri.
: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
: Rolf Symons, MD, one of the authors, has significant statistical expertise.
: Written informed consent was obtained from all patients prior to their participation in the study.
: This was a prospective study approved by the institutional review board at the National Human Genome Research Institute (NHGRI).
: Clinical aspects of 60 patients of the present cohort were previously reviewed by Estrada-Veras et al. in the paper titled “The clinical spectrum of Erdheim-Chester disease: an observational cohort study” [CitationRef removed].
: • observational• single-centre• prospective